Body weight cycling, also known as “yo-yo dieting,” is associated with a 25%-36% increased risk for diabetic kidney disease ...

The first clinical trials using organs from genetically modified pigs offer hope to patients with kidney failure, who face a ...

Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with ...

A year after guidelines were revised to remove the use of race in eGFR, many labs and pathologists were still relying on the ...

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

Older adults with advanced kidney disease are often motivated to receive a transplant but may face emotional and psychosocial ...

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in ...

Chronic kidney disease is a common complication for people living with type 2 diabetes. Diabetes is the leading cause of ...

Kidney disease affects millions of Americans, with Black communities facing disproportionately higher risks due to genetic factors, socioeconomic challenges, ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...